Angela V West

USPTO Granted Patents = 15 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 8.6

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

8 out of 125

Forma Therapeutics, Inc.

patents

2 out of 69

Ariad Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

patents

Years Active: 2017-2025

where 'Filed Patents' based on already Granted Patents

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421233 - WRN inhibitors (2025-09-23),

2. 12378242 - Inhibiting CREB binding protein (CBP) (2025-08-05),

3. 12351577 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) (2025-07-08),

4. 12344609 - WRN inhibitors (2025-07-01),

5. 12331046 - CTPS1 inhibitors and uses thereof (2025-06-17),

6. 12325697 - CBL-B modulators and uses thereof (2025-06-10),

7. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

8. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

9. 11787803 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2023-10-17),

10. 11535618 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2022-12-27),

11. 11292791 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2022-04-05),

12. 11254674 - Inhibiting CREB binding protein (CBP) (2022-02-22),

13. 10870648 - Inhibiting CREB binding protein (CBP) (2020-12-22),

14. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

15. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

Title: Celebrating the Innovations of Angela V. West

Introduction: Angela V. West is a prominent inventor based in Franklin, Massachusetts, known for her significant contributions in the field of kinase inhibition and ubiquitin-specific protease inhibitors. With a total of nine patents to her name, Angela has developed groundbreaking compounds that have the potential to influence the treatment of various diseases associated with kinase activity.

Latest Patents: Angela's latest patents focus on innovative compounds and pharmaceutical compositions. One patent describes heteroaryl compounds that modulate kinase activity, particularly targeting mutant EGFR and mutant HER2 kinase activity. This work promises to advance therapeutic options for conditions related to these specific kinases. Another recent patent features fused pyrrolines that act as USP30 inhibitors, providing new avenues for pharmaceutical compositions that can have significant medical use.

Career Highlights: Throughout her career, Angela has been affiliated with leading biotechnology companies, including Forma Therapeutics, Inc. and Ariad Pharmaceuticals, Inc. These experiences have allowed her to explore cutting-edge research and translate her scientific findings into practical applications that address pressing health issues.

Collaborations: Angela has collaborated with esteemed colleagues in her field, notably Hongbin Li and Steven Gregory Mischke. These partnerships have contributed to a dynamic research environment that fosters innovation and the development of novel therapeutic strategies.

Conclusion: Angela V. West's work exemplifies the spirit of innovation and dedication to advancing medical science. Her patents reflect a commitment to improving patient outcomes through targeted therapeutic approaches, and her career continues to inspire future generations of inventors in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.